Anti-Infectives are the various drugs used to treat the infection caused by pathogens. Anti-Infective drugs include antibacterial drugs, antiviral drugs and antifungal drugs, among them, antibiotics occupy the largest market share.
The antibiotics market was valued at USD 65.21 billion in 2016 and is expected to witness a CAGR of 4.0% over the forecast period. Increasing efforts are being witnessed toward the development of advanced products.
Furthermore, supportive government legislations, such as the Generating Antibiotics Incentives Now (GAIN) Act are expected to expedite the approval process. GAIN Act has provisions which facilitate development of therapy against antibiotic resistant pathogens.
The primary factor for any product or market to flourish is its demand. This demand is anticipated to increase due to the predicted rise in the incidence of infectious diseases across the globe over the forecast period, emerging infectious diseases, and the current gap in supply and demand of antibiotics.
However, development of resistance, especially in case of bacterial infections is on the rise and renders the antibiotic or its entire class ineffective, thereby critically impacting the overall antibiotic market. Owing to the high cost of development of the drugs, such incidents act as catalysts in increasing costs of finding alternatives.
The key consumption markets locate at developed countries. The Asia-Pacific takes the market share of 38%, followed by Europe with 27%. Global consumption market has a quicker growing speed of CAGR 5.75%.
Key players in the global Anti-Infectives market include:
Astra Zeneca
Johnson & Johnson
GlaxoSmithKline
Novartis
Pfizer
Wockhardt
Roche
Sanofi
Merck
YRPG